Angiodynamics Inc. ANGO
Medical/Dental Instruments · IPO 2004 · data as of November 13, 2026
Angiodynamics Inc. (ANGO) is a healthcare company listed in the US with a market value of about $499M. In the twelve months to August 31, 2026 it had revenue of $325M and net income of -$33M, a net margin of -10.1%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 345.7, 5-year revenue growth of 2% a year, a 5-year average ROIC of -29%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 77% below the current price.
About Angiodynamics
Angiodynamics is listed in the US and classified in medical/dental instruments, IPO year 2004. Revenue went from $354M in 2016 to $320M in 2026, a decline of about 1.0% a year. It was profitable in 3 of the last 10 years in our data. Its share count rose by 5% over three years (dilution for shareholders). It spends 9% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Positive free cash flow
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $325M | $320M | $292M | $304M | $339M | $316M | $291M | $264M | $271M | $262M | $350M |
| Net income | -$33M | -$37M | -$34M | -$184M | -$52M | -$27M | -$32M | -$167M | $61M | $16M | $5M |
| Free cash flow | $1M | $508000 | -$15M | -$31M | -$4M | -$11M | $19M | -$22M | $34M | $39M | $53M |
| EPS (diluted) | $-0.78 | $-0.88 | $-0.83 | $-4.59 | $-1.33 | $-0.68 | $-0.82 | $-4.39 | $1.64 | $0.44 | $0.14 |
| Net margin | -10.1% | -11.5% | -11.6% | -60.7% | -15.5% | -8.4% | -10.8% | -63.1% | 22.7% | 6.2% | 1.4% |
| ROIC | — | -17.9% | -21.3% | -87.5% | -11.4% | -5.5% | -6.9% | -35.6% | -0.9% | -1.8% | -1.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $19.75, 66% above the current price; targets range from $17.00 to $24.00; the consensus rating is “none”; expected EPS is $-0.28 for the fiscal year ending May 31, 2027.
Frequently asked questions
Is Angiodynamics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 77% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Angiodynamics pay a dividend?
Not currently.
Is Angiodynamics a good stock to buy?
We do not give buy or sell advice. Angiodynamics scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.